LEO Pharma A/S financials
LEO Pharma A/S
Country: DK Reporting currency: DKK Latest annual report: 2025-12-31
LEI:
52990077KVK7QCK2NG31 Financial statements
(DKK, as reported — unscaled; 96 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | DKK 13.50B | DKK 12.45B |
| Cost of sales | DKK 5.26B | DKK 4.93B |
| Gross profit | DKK 8.24B | DKK 7.52B |
| Administrative expenses | DKK 1.35B | DKK 1.48B |
| Operating profit (EBIT) | DKK 2.28B | -DKK 1.14B |
| Finance costs | DKK 688.0M | DKK 946.0M |
| Profit before tax | DKK 1.71B | -DKK 1.96B |
| Income tax expense | -DKK 776.0M | -DKK 181.0M |
| Profit for the year | DKK 2.49B | -DKK 1.78B |
| Total comprehensive income | DKK 2.52B | -DKK 1.88B |
| Cash flow statement | ||
| Net cash from operating activities | DKK 1.25B | DKK 265.0M |
| Net cash from investing activities | DKK 620.0M | -DKK 317.0M |
| Purchase of PP&E (capex) | DKK 256.0M | DKK 259.0M |
| Purchase of intangibles | DKK 870.0M | DKK 61.0M |
| Net cash from financing activities | -DKK 1.88B | DKK 79.0M |
| Proceeds from borrowings | DKK 950.0M | DKK 1.17B |
| Repayments of borrowings | DKK 2.91B | DKK 1.16B |
| Lease liability payments | DKK 93.0M | DKK 110.0M |
| Balance sheet | ||
| Total assets | DKK 20.45B | DKK 20.15B |
| Non-current assets | DKK 12.16B | DKK 11.48B |
| Property, plant & equipment | DKK 4.37B | DKK 4.45B |
| Right-of-use assets | DKK 212.0M | DKK 208.0M |
| Intangible assets & goodwill | DKK 4.55B | DKK 4.75B |
| Current assets | DKK 8.28B | DKK 8.67B |
| Inventories | DKK 4.05B | DKK 4.97B |
| Trade & other receivables | DKK 3.04B | DKK 2.37B |
| Cash & equivalents | DKK 235.0M | DKK 227.0M |
| Total equity | DKK 5.26B | DKK 2.70B |
| Non-current liabilities | DKK 9.36B | DKK 11.53B |
| Long-term borrowings | DKK 8.47B | DKK 10.41B |
| Lease liabilities (non-current) | DKK 168.0M | DKK 164.0M |
| Current liabilities | DKK 5.83B | DKK 5.92B |
| Short-term borrowings | DKK 889.0M | DKK 502.0M |
| Lease liabilities (current) | DKK 66.0M | DKK 82.0M |
| Deferred tax liabilities | DKK 44.0M | DKK 37.0M |
| Derived metrics | ||
| Free cash flow | DKK 999.0M | DKK 6.0M |
| Operating margin | 16.9% | -9.2% |
| Net margin | 18.4% | -14.3% |
| Return on equity | 47.3% | -65.7% |
| Cash conversion ratio | 0.50× | -0.15× |
| Capex coverage | 4.90× | 1.02× |
| Other reported items | ||
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | DKK 1.47B | DKK 1.74B |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | -DKK 1.74B | -DKK 3.0M |
| Cash Flows From Used In Increase Decrease In Current Borrowings | DKK 387.0M | DKK 220.0M |
| Current Tax Assets Current | DKK 337.0M | DKK 553.0M |
| Current Tax Liabilities Current | DKK 173.0M | DKK 112.0M |
| Current Tax Liabilities Noncurrent | DKK 32.0M | DKK 65.0M |
| Deferred Tax Assets | DKK 2.49B | DKK 1.48B |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | DKK 11.0M | -DKK 16.0M |
| Equity and Liabilities | DKK 20.45B | DKK 20.15B |
| Finance Income | DKK 122.0M | DKK 132.0M |
| Gains Losses On Cash Flow Hedges Before Tax | DKK 128.0M | -DKK 117.0M |
| Income Tax Relating To Components of Other Comprehensive Income | DKK 25.0M | -DKK 23.0M |
| Income Tax Relating To Components of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss | DKK 20.0M | -DKK 27.0M |
| Income Tax Relating To Components of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss | DKK 5.0M | DKK 4.0M |
| Income Taxes Paid Refund Classified As Operating Activities | DKK 24.0M | DKK 361.0M |
| Increase Decrease In Cash and Cash Equivalents | -DKK 3.0M | DKK 27.0M |
| Increase Decrease In Working Capital | DKK 150.0M | -DKK 474.0M |
| Increase Decrease Through Sharebased Payment Transactions | DKK 45.0M | DKK 38.0M |
| Increase Decrease Through Transactions With Owners | DKK 42.0M | DKK 58.0M |
| Interest Paid Classified As Operating Activities | DKK 597.0M | DKK 857.0M |
| Interest Received Classified As Operating Activities | DKK 24.0M | DKK 91.0M |
| Issue of Equity | DKK 0 | DKK 29.0M |
| Issued Capital | DKK 384.0M | DKK 383.0M |
| Liabilities | DKK 15.18B | DKK 17.45B |
| Noncurrent Recognised Assets Defined Benefit Plan | DKK 239.0M | DKK 206.0M |
| Noncurrent Recognised Liabilities Defined Benefit Plan | DKK 61.0M | DKK 75.0M |
| Other Adjustments For Noncash Items | -DKK 10.0M | DKK 322.0M |
| Other Comprehensive Income | DKK 27.0M | -DKK 103.0M |
| Other Comprehensive Income Before Tax Cash Flow Hedges | DKK 92.0M | -DKK 122.0M |
| Other Comprehensive Income Before Tax Exchange Differences On Translation | -DKK 28.0M | -DKK 31.0M |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | -DKK 12.0M | DKK 27.0M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -DKK 28.0M | -DKK 31.0M |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | -DKK 12.0M | DKK 27.0M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | DKK 44.0M | -DKK 126.0M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | -DKK 17.0M | DKK 23.0M |
| Other Current Payables | DKK 2.70B | DKK 2.62B |
| Other Current Receivables | DKK 620.0M | DKK 553.0M |
| Other Inflows Outflows of Cash Classified As Financing Activities | -DKK 209.0M | -DKK 61.0M |
| Other Longterm Provisions | DKK 295.0M | DKK 307.0M |
| Other Noncurrent Financial Assets | DKK 113.0M | DKK 194.0M |
| Other Noncurrent Liabilities | DKK 285.0M | DKK 464.0M |
| Other Operating Income Expense | DKK 1.74B | DKK 13.0M |
| Other Reserves | -DKK 326.0M | -DKK 370.0M |
| Other Shortterm Provisions | DKK 980.0M | DKK 1.16B |
| Payments To Acquire Or Redeem Entitys Shares | DKK 7.0M | DKK 9.0M |
| Proceeds From Issuing Shares | DKK 0 | DKK 29.0M |
| Proceeds From Sale Or Issue of Treasury Shares | DKK 4.0M | DKK 0 |
| Proceeds From Sales of Intangible Assets Classified As Investing Activities | DKK 1.74B | DKK 0 |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | DKK 8.0M | DKK 3.0M |
| Purchase of Treasury Shares | DKK 7.0M | DKK 9.0M |
| Reclassification Adjustments On Cash Flow Hedges Before Tax | DKK 36.0M | -DKK 5.0M |
| Research and Development Expense | DKK 1.40B | DKK 2.27B |
| Retained Earnings | DKK 5.20B | DKK 2.69B |
| Sale Or Issue of Treasury Shares | DKK 4.0M | DKK 0 |
| Trade and Other Current Payables To Trade Suppliers | DKK 1.02B | DKK 1.44B |
Methodology
Every line item above is a fact tagged in LEO Pharma A/S's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (DKK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.